Latest
Börse Express Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 682
- Sources here
- 21
- Companies here
- 13
Search results
Stored financial headlines
Active search
682 matching headlines
Ticker or company: ASCMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen
Wall Street Zen has upgraded Ascendis Pharma A/S (NASDAQ:ASND) from a "hold" to a "buy" rating, aligning with a consensus "Buy" rating and an average price target of $299.24 from other analysts. The company's shares opened 0.9% higher at $248.50, and it recently reported …
ASND
main company
Sharemaestro market context
Trend signal active
52 weeks +27.9%
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes
Erasca, Inc. has filed an amended passive investment disclosure (SCHEDULE 13G/A) detailing updated insider ownership. Jonathan E. Lim beneficially owns 10.4% of the common stock, while Conyee T. Lim holds a 5.6% beneficial stake. These figures are based on 349,762,035 shares outstanding as of …
ERAS
main company
Sharemaestro market context
Trend signal active
52 weeks +1048.8% · Next-week setup positive 63.8%
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says
Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …
ASND
main company
Sharemaestro market context
Trend signal active
52 weeks +27.9%
Zacks Flags Adecco (OTC: AHEXY), Boise Cascade (NYSE: BCC) And Capital Southwest (NASDAQ: CSWC) As Strong Sells
Zacks Investment Research has issued "Strong Sell" ratings for Adecco Group AG (AHEXY), Boise Cascade Company (BCC), and Capital Southwest Corporation (CSWC). This downgrade is based on significant downward revisions to their earnings estimates, with Adecco's current year earnings estimate revised down 10.6%, Boise …
BCC
main company
Sharemaestro market context
Price above Trend Line
52 weeks -7.7%
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages
Erasca, Inc. (NASDAQ:ERAS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.91. Despite a recent 3.9% decline in shares and missing analyst expectations for its quarterly loss, institutional investors hold a significant 67.78% of the …
ERAS
main company
Sharemaestro market context
Trend signal active
52 weeks +1048.8% · Next-week setup positive 63.8%
Guggenheim raises Erasca stock price target to $21 on pipeline progress
Guggenheim has increased its price target for Erasca Inc. (NASDAQ: ERAS) to $21 from $20, maintaining a Buy rating, citing confidence in the company's RAS inhibitor pipeline progress. This follows Erasca's second-quarter 2026 results and a pipeline update, including advanced development plans for ERAS-0015 …
ERAS
main company
Sharemaestro market context
Trend signal active
52 weeks +1048.8% · Next-week setup positive 63.8%
Boise Cascade (BCC) sees Wellington group report 5.19% beneficial stake
Wellington Management Group LLP, along with its affiliated entities, has reported a beneficial ownership of 5.19% in Boise Cascade Company (BCC), totaling 1,824,952 shares of common stock as of June 30, 2026. The group exercises shared voting power over 1,627,277 shares and shared dispositive …
BCC
main company
Sharemaestro market context
Price above Trend Line
52 weeks -7.7%
Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma A/S reported strong Q2 2026 results, with total revenue more than doubling year-over-year due to increased demand for its TransCon-based therapies. Yorvipath and Yuviwel showed significant growth and early momentum, respectively, contributing to the company's positive financial outlook. Ascendis also outlined pipeline …
ASND
main company
Sharemaestro market context
Trend signal active
52 weeks +27.9%
Masco (MAS): Buy, Sell, or Hold Post Q2 Earnings?
Masco (MAS): Buy, Sell, or Hold Post Q2 Earnings? Masco currently trades at $75.17 per share and has shown little upside over the past six months, posting a small loss of 1.7%. The stock also fell short of the S&P 500's 11.7% gain during …
MAS
main company
Sharemaestro market context
Trend signal active
52 weeks -0.3%
How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales
LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. Despite these challenges, the company reinforced its growth narrative, though the revised guidance highlights …
LMAT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.3% · Next-week setup positive 60.5%
GEHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies …
LMAT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.3% · Next-week setup positive 60.5%
LeMaitre Vascular remains a Buy despite 31% pullback; strong organic growth and record margins support outlook.
LeMaitre Vascular's stock experienced a 31% drop after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages. However, the company demonstrates strong underlying demand with 10% organic sales growth and record-high margins, driven by its fastest-growing product, Artegraft. Despite the …
LMAT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.3% · Next-week setup positive 60.5%
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Ascentage Pharma Group International will participate in the Evercore ISI 2nd Annual China Biotech Summit in Shanghai, Pudong from August 17-19, 2026. Management will engage in a fireside chat on August 18, 2026, and conduct one-on-one investor meetings. The company is a global biopharmaceutical …
Sharemaestro market context Price below Trend Line 52 weeks -60.3% · Next-week setup negative 44.0%Ascendis Pharma Reports Second Quarter 2026 Financial Results
Ascendis Pharma announced strong financial results for Q2 2026, with total product revenue reaching €315 million, a 105% year-over-year increase, driven by YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company reported a net profit of €207 million and significant pipeline advancements, including long-term data for YORVIPATH, …
ASND
main company
Sharemaestro market context
Trend signal active
52 weeks +27.9%
Ascendis Pharma A/S Q2 2026 Earnings Call Transcript
Ascendis Pharma A/S announced strong Q2 2026 financial results, with total revenue more than doubling year-over-year to €339 million, driven by robust demand for their TransCon products, YORVIPATH, YUVIWEL, and SKYTROFA. The company reiterated its long-term growth targets, including €5 billion in revenue by …
ASND
main company
Sharemaestro market context
Trend signal active
52 weeks +27.9%